Actinium Pharmaceuticals, Inc. has reported its financial results for the fiscal year ending December 31, 2025, revealing a total revenue of $90,000, primarily from a grant awarded by the National Institutes of Health. This marks a significant increase from the previous year, where the company reported no revenue. However, the company continues to operate at a loss, with a net loss of $33.9 million for 2025, a decrease from the $38.2 million loss reported in 2024. The reduction in losses is attributed to a decrease in research and development expenses, which fell by $8.9 million to $21.1 million, largely due to reduced external costs and a decrease in headcount.
In terms of operational developments, Actinium has made strides in its clinical pipeline, focusing on targeted radiotherapies for oncology. The company is advancing several product candidates, including Actimab-A and Iomab-B, which are in various stages of clinical trials. Actimab-A is being developed in collaboration with the National Cancer Institute and is positioned as a potential treatment for acute myeloid leukemia and myelodysplastic syndromes. The company has also established a partnership with Immedica for the commercialization of Iomab-B in the EUMENA region, which is expected to generate milestone payments and royalties upon regulatory approval.
Actinium's employee headcount as of March 2026 stands at 25, with a significant portion engaged in research and development activities. The company has also been proactive in managing its operational costs, which has contributed to the reduction in net losses. However, the company remains dependent on external funding to support its ongoing clinical trials and development efforts. As of the filing date, Actinium anticipates that its existing resources will be sufficient to fund operations for more than 12 months, but acknowledges the need for additional financing to support future growth and development.
Looking ahead, Actinium Pharmaceuticals is focused on advancing its clinical programs and expanding its manufacturing capabilities. The company is in the process of establishing a cGMP manufacturing facility, expected to be operational in the second half of 2026, which will enhance its ability to produce its radiopharmaceutical products at scale. The company’s strategic outlook emphasizes the importance of securing partnerships and collaborations to facilitate the development and commercialization of its product candidates, while navigating the competitive landscape of the biopharmaceutical industry.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals develops targeted radiotherapies using alpha-emitting isotopes to treat advanced cancers, including myeloid malignancies, solid tumors, and conditioning for cell and gene therapies. Its clinical-stage pipeline features Actimab-A for AML and MDS, Iomab-ACT for conditioning prior to cellular therapies, and ATNM-400 for prostate cancer. The company integrates radioisotope production, drug manufacturing, and clinical development, leveraging proprietary Ac-225 technology and a broad patent portfolio.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.